SLNO icon

Soleno Therapeutics

68.22 USD
-3.23
4.52%
At close Apr 1, 3:59 PM EDT
After hours
67.87
-0.35
0.51%
1 day
-4.52%
5 days
36.82%
1 month
48.95%
3 months
49.25%
6 months
37.46%
Year to date
49.25%
1 year
64.43%
5 years
84.13%
10 years
39.94%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

196% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 26

100% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 24

16% more funds holding

Funds holding: 142 [Q3] → 165 (+23) [Q4]

2% less call options, than puts

Call options by funds: $120M | Put options by funds: $123M

4% less capital invested

Capital invested by funds: $2.38B [Q3] → $2.29B (-$85.7M) [Q4]

2.89% less ownership

Funds ownership: 121.26% [Q3] → 118.37% (-2.89%) [Q4]

11% less funds holding in top 10

Funds holding in top 10: 9 [Q3] → 8 (-1) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$81
19%
upside
Avg. target
$103
51%
upside
High target
$123
80%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
34% 1-year accuracy
117 / 342 met price target
47%upside
$100
Buy
Maintained
31 Mar 2025
Stifel
James Condulis
67% 1-year accuracy
2 / 3 met price target
58%upside
$108
Buy
Maintained
28 Mar 2025
Guggenheim
Debjit Chattopadhyay
32% 1-year accuracy
7 / 22 met price target
19%upside
$81
Buy
Maintained
28 Mar 2025
Laidlaw & Co.
Yale Jen
50% 1-year accuracy
3 / 6 met price target
54%upside
$105
Buy
Maintained
27 Mar 2025
Baird
Brian Skorney
36% 1-year accuracy
8 / 22 met price target
50%upside
$102
Outperform
Maintained
27 Mar 2025

Financial journalist opinion

Based on 4 articles about SLNO published over the past 30 days

Positive
Zacks Investment Research
5 days ago
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Positive
Investors Business Daily
5 days ago
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed. The post Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher appeared first on Investor's Business Daily.
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
Positive
Benzinga
5 days ago
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
Neutral
GlobeNewsWire
5 days ago
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
Neutral
GlobeNewsWire
2 months ago
Soleno Therapeutics to Participate in Upcoming February Investor Conferences
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:
Soleno Therapeutics to Participate in Upcoming February Investor Conferences
Neutral
GlobeNewsWire
3 months ago
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million.
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
Neutral
GlobeNewsWire
4 months ago
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Neutral
GlobeNewsWire
4 months ago
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
Neutral
GlobeNewsWire
4 months ago
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, being held November 16-18, 2024 in Liverpool, UK.
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
Positive
Seeking Alpha
5 months ago
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects.
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Charts implemented using Lightweight Charts™